Latest news


Fourth quarter and preliminary 2018 results

Posted on Feb 13, 2019

Oslo (Norway), 13 February 2019 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company today announces its interim fourth quarter and preliminary 2018 result. Please find enclosed the report and presentation. Solid performance through 2018, moving towards initiation of the pivotal “RELEASE” study The fully underwritten rights issue of NOK 360 million completed in […]

Posted on Feb 6, 2019

Oslo, Norway, 05 February 2019 – PCI Biotech invites to a presentation of the company’s fourth quarter and preliminary 2018 report on Wednesday 13 February 2019 at Oslo Cancer Cluster Innovation Park. Time: Wednesday February 13, 08:30am – 09:30am CET (local time). Venue: Jónas Einarsson aud. (2nd floor, entrance 2B), Oslo Cancer Cluster Innovation Park, […]

Preliminary confirmation of safety read-out from the fimaChem Phase I extension study in bile duct cancer

Posted on Dec 20, 2018

Oslo (Norway), 20 December 2018 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company today announced preliminary confirmation that the safety endpoint has been reached in the Phase I extension study without the report of any adverse reactions which would limit the proposed plan of including up to two fimaCHEM treatments in the pivotal […]